In This Issue
In the Spotlight
Cancer Hallmarks Reviews
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Ivodesinib and venetoclax with or without azacitidine are safe and effective against IDH1-mutated myeloid cancers, with molecular correlates illustrating potential resistance-limiting mechanisms of combination therapy.
The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
Hypusination of the eIF5A translation factor is necessary for the development and maintenance of MYC-driven lymphoma, where hypusinated eIF5A controls the translation of factors that are essential for cell-cycle transit and DNA replication.
Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia
A collection of iPSC lines derived from AML patients capture leukemia genomes and phenotypes and produce xenografts nearly identical to the matched primary PDXs. iPSCs from different AML clones uniquely empower the study of subclonal mutations.